x

RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Jul 31, 2017 1:00 PM ET

BUYINS.NET: AVEO SqueezeTrigger Price is $2.52. There is $4,889,367 That Short Sellers Still Need To Cover.

iCrowdNewswire - Jul 31, 2017

July 31, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) in real time and just received an alert that AVEO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 602,070,983 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $2.52. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .

From July 2012 to July 2017, an aggregate amount of 602,070,983 shares of AVEO have been shorted for a total dollar value of $1,518,020,947. The AVEO SqueezeTrigger price of $2.52 is the volume weighted average price that all shorts are short in shares of AVEO. There is still approximately $4,889,367 of potential short covering in shares of AVEO.

Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) – AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts..

The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor – Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new “Fair Market Making Requirements”
Naked Shorts (RegSho) – Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

Earnings – Predicts probability, price move and length of move before and after all US stock earnings reports
Seasonality – Predicts probability, price move and length of move based on exact time of year for all US stocks
Group Correlation – Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups
SqueezeTrigger – Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Valuation – Tracks all known valuation models and applies them.
GATS – Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies.
PatternScan – Automates tracking of every technical pattern and predicts next move in stocks.
Insider – Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders
Events – Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact:

Tom Ronk, CEO
BUYINS.NET
tomronk@gmail.com
800-715-9999

Contact Information:

Tom Ronk, CEO
BUYINS.NET
tomronk@gmail.com
800-715-9999

View Related News >